Cargando…

Improvement of Alveolar Hemorrhaging in an Elderly and Renally Impaired Patient with Relapsing Anti-neutrophil Cytoplasmic Autoantibody-associated Vasculitis by Single Infusion of Rituximab

Rituximab (RTX) has become a therapeutic option for inducing remission of anti-neutrophil cytoplasmic autoantibody-associated vasculitis (AAV). However, the optimum dosage of RTX to induce remission of AAV and reduce adverse events, such as infection, remains unclear. We herein report an elderly and...

Descripción completa

Detalles Bibliográficos
Autores principales: Oda, Keiko, Ishikawa, Eiji, Ito, Takayasu, Mizoguchi, Shoko, Hirabayashi, Yosuke, Suzuki, Yasuo, Haruki, Ayumi, Fujimoto, Mika, Murata, Tomohiro, Katayama, Kan, Onishi, Takahiro, Ito, Masaaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287994/
https://www.ncbi.nlm.nih.gov/pubmed/29984747
http://dx.doi.org/10.2169/internalmedicine.0936-18
Descripción
Sumario:Rituximab (RTX) has become a therapeutic option for inducing remission of anti-neutrophil cytoplasmic autoantibody-associated vasculitis (AAV). However, the optimum dosage of RTX to induce remission of AAV and reduce adverse events, such as infection, remains unclear. We herein report an elderly and renally impaired patient with alveolar hemorrhaging due to refractory AAV who was successfully treated with single infusion of RTX. Single infusion of RTX may be a therapeutic option in refractory AAV patients who are vulnerable to infections.